133 related articles for article (PubMed ID: 29126091)
1. Older cancer patients in cancer clinical trials are underrepresented. Systematic literature review of almost 5000 meta- and pooled analyses of phase III randomized trials of survival from breast, prostate and lung cancer.
Dunn C; Wilson A; Sitas F
Cancer Epidemiol; 2017 Dec; 51():113-117. PubMed ID: 29126091
[TBL] [Abstract][Full Text] [Related]
2. Timing of first-line cancer treatments - early versus late - a systematic review of phase III randomized trials.
Mhaskar AR; Quinn G; Vadaparampil S; Djulbegovic B; Gwede CK; Kumar A
Cancer Treat Rev; 2010 Dec; 36(8):621-8. PubMed ID: 20444550
[TBL] [Abstract][Full Text] [Related]
3. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
[TBL] [Abstract][Full Text] [Related]
4. Variation, precision and validity of 1-year survival estimates for lung, breast, colon and prostate cancer in South East England primary care trusts.
Lake J; Mak V; Møller H; Davies EA
Public Health; 2012 Jan; 126(1):57-63. PubMed ID: 22153886
[TBL] [Abstract][Full Text] [Related]
5. Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.
Fenton JJ; Weyrich MS; Durbin S; Liu Y; Bang H; Melnikow J
JAMA; 2018 May; 319(18):1914-1931. PubMed ID: 29801018
[TBL] [Abstract][Full Text] [Related]
6. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
[TBL] [Abstract][Full Text] [Related]
7. Influence of Age on Guideline-Concordant Cancer Care for Elderly Patients in the United States.
Fang P; He W; Gomez DR; Hoffman KE; Smith BD; Giordano SH; Jagsi R; Smith GL
Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):748-757. PubMed ID: 28366580
[TBL] [Abstract][Full Text] [Related]
8. Overall and cancer-specific survival of patients with breast, colon, kidney, and lung cancers with and without chronic lymphocytic leukemia: a SEER population-based study.
Solomon BM; Rabe KG; Slager SL; Brewer JD; Cerhan JR; Shanafelt TD
J Clin Oncol; 2013 Mar; 31(7):930-7. PubMed ID: 23341508
[TBL] [Abstract][Full Text] [Related]
9. Screening for prostate cancer: an updated Cochrane systematic review.
Ilic D; O'Connor D; Green S; Wilt TJ
BJU Int; 2011 Mar; 107(6):882-91. PubMed ID: 21392207
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of restrictive versus liberal transfusion strategies in older adults from nine randomised controlled trials: a systematic review and meta-analysis.
Simon GI; Craswell A; Thom O; Fung YL
Lancet Haematol; 2017 Oct; 4(10):e465-e474. PubMed ID: 28919087
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline.
Cheng S; Evans WK; Stys-Norman D; Shepherd FA;
J Thorac Oncol; 2007 Apr; 2(4):348-54. PubMed ID: 17409809
[TBL] [Abstract][Full Text] [Related]
12. Current vaccination strategies for prostate cancer.
Joniau S; Abrahamsson PA; Bellmunt J; Figdor C; Hamdy F; Verhagen P; Vogelzang NJ; Wirth M; Van Poppel H; Osanto S
Eur Urol; 2012 Feb; 61(2):290-306. PubMed ID: 22001436
[TBL] [Abstract][Full Text] [Related]
13. [Volume and health outcomes: evidence from systematic reviews and from evaluation of Italian hospital data].
Amato L; Colais P; Davoli M; Ferroni E; Fusco D; Minozzi S; Moirano F; Sciattella P; Vecchi S; Ventura M; Perucci CA
Epidemiol Prev; 2013; 37(2-3 Suppl 2):1-100. PubMed ID: 23851286
[TBL] [Abstract][Full Text] [Related]
14. The Intersection of Palliative Care and Survivorship.
Kennedy Sheldon L
Clin J Oncol Nurs; 2017 Feb; 21(1):11. PubMed ID: 28107321
[TBL] [Abstract][Full Text] [Related]
15. Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline.
Noble J; Ellis PM; Mackay JA; Evans WK;
J Thorac Oncol; 2006 Nov; 1(9):1042-58. PubMed ID: 17409993
[TBL] [Abstract][Full Text] [Related]
16. Five-year relative survival from prostate, breast, colorectal and lung cancer.
Ellison LF; Gibbons L;
Health Rep; 2001 Dec; 13(1):23-34. PubMed ID: 15069806
[TBL] [Abstract][Full Text] [Related]
17. Mortality from all cancers and lung, colorectal, breast and prostate cancer by country of birth in England and Wales, 2001-2003.
Wild SH; Fischbacher CM; Brock A; Griffiths C; Bhopal R
Br J Cancer; 2006 Apr; 94(7):1079-85. PubMed ID: 16523198
[TBL] [Abstract][Full Text] [Related]
18. The project data sphere initiative: accelerating cancer research by sharing data.
Green AK; Reeder-Hayes KE; Corty RW; Basch E; Milowsky MI; Dusetzina SB; Bennett AV; Wood WA
Oncologist; 2015 May; 20(5):464-e20. PubMed ID: 25876994
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
